🔎 Trials Near Me

Home › Flu › NCT02735707

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

RecruitingPhase 3

Who can join

28 Days · All sexes

Full eligibility criteria
The eligibility criteria for the Platform are applied at multiple levels. One level is that there are inclusion and exclusion criteria that determine eligibility for randomization within the Platform. Another level is that, once eligible for inclusion within the Platform, additional criteria (typically exclusion criteria) are applied that are specific to each domain. Finally, intervention-level eligibility criteria may be applied for interventions within a domain. A patient is eligible for inclusion within a domain when:

* All Platform inclusion criteria are met
* None of the Platform exclusion criteria are met
* Domain-specific eligibility criteria are met
* The patient is eligible for at least two interventions within a domain

As such, the key "inclusion criteria" for being eligible for a domain are that the patient is eligible for the Platform.

\--

PLATFORM INCLUSION CRITERIA:

1. Hospitalised patient
2. Acute respiratory tract infection
3. Aged 28 days or older

PLATFORM EXCLUSION CRITERIA:

1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
2. Patient is expected to be discharged from hospital within the next 24 hours
3. Previous participation in this REMAP within the last 90 days

DOMAIN-SPECIFIC ELIGIBILITY CRITERIA:

Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).

About the study

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.

The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised patients admitted to intensive care with respiratory tract infections.

In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.

REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.

What is being tested

Sponsor: UMC Utrecht · Participants: 20,000 · Started: Apr 11, 2016

Contact the study team

Official record on ClinicalTrials.gov — NCT02735707

Locations in the U.S.

FloridaUniversity of Florida, Jacksonville
GeorgiaAugusta University, Augusta (Not yet recruiting)
IllinoisUniversity of Illinois Health, Chicago
LouisianaTulane Medical Center, New Orleans (Not yet recruiting)
MichiganUniversity of Michigan, Ann Arbor
New YorkMemorial Sloan Kettering Cancer Center, New York
North CarolinaWake Forest Baptist Health, Winston-Salem (Not yet recruiting)
OhioThe Ohio State University Wexner Medical Center, Columbus
OregonOregon Health and Science University, Portland
PennsylvaniaUniversity of Pittsburgh Medical Centre, Pittsburgh
Rhode IslandBrown University - Rhode Island Hospital, Providence (Not yet recruiting)

Conditions

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.